Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( (AU:RMD) ) is now available.
ResMed Inc. has filed a Form 144 notice indicating the proposed sale of securities by Michael J. Rider, an officer of the company. The filing outlines the sale of 41 common shares with an aggregate market value of $9,994.98, scheduled for June 2, 2025. This transaction follows previous sales by Rider in March and April 2025, reflecting ongoing personal financial management activities. The announcement does not indicate any adverse information regarding ResMed’s current or future operations, suggesting stability in the company’s market position.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$33.70 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
More about Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
ResMed Inc. operates in the healthcare industry, primarily focusing on the development and manufacturing of products for the treatment of sleep disorders, respiratory care, and connected health solutions. The company is known for its innovative devices and software solutions that aim to improve the quality of life for patients with sleep apnea and other chronic respiratory conditions.
Average Trading Volume: 1,317,793
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$55.21B
For detailed information about RMD stock, go to TipRanks’ Stock Analysis page.